A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

NCT06952530 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the safety and effectiveness of the medication orforglipron (LY3502970) in adults who have both high blood pressure and obesity or overweight.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 487 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-04 · est. completion 2027-09

Where 99 sites · Argentina, China, Czechia, Germany, Greece, India, Japan, Poland, Puerto Rico, Spain, United States

What this study is testing ClinicalTrials.gov NCT06952530 ↗

Description as written by the study sponsor.

GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally
Placebo Drug

placebo administered

Main thing measured	Change from Baseline in office Systolic Blood Pressure (SBP)
Sponsor	Eli Lilly and Company
Conditions studied	Hypertension
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06952530 ↗